Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 08:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
November 07, 2025 09:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at SITC 2025 40th Anniversary Annual Meeting

− Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC − Supports the planned Phase 1 cohort of FX-909 in combination with pembrolizumab; initiating in...
November 03, 2025 09:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics to Participate in Upcoming Investor Conferences in November

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
October 30, 2025 09:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics to Present Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at Upcoming SITC 2025 40th Anniversary Annual Meeting

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference

FX-909, the first small molecule targeting PPARG to be tested in humans, showed monotherapy activity in advanced urothelial carcinoma with a favorable safety profileStrong safety, tolerability and...
October 21, 2025 07:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
October 14, 2025 08:26 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
August 27, 2025 08:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics to Participate in Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
August 05, 2025 07:30 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
May 28, 2025 08:30 ET | Source: Flare Therapeutics

Flare Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...